Our Pricing

Saxenda Injection UK: Complete Guide to Liraglutide Weight Loss Treatment

Published on: June 03, 2026

Saxenda injection UK availability has transformed weight management options for thousands of patients seeking clinically proven support for sustainable weight loss. As a UK-registered pharmacy with over a decade of experience dispensing liraglutide injections, we've helped patients achieve meaningful results through proper clinical assessment and ongoing pharmaceutical care. This comprehensive guide covers everything you need to know about accessing Saxenda in the UK, from prescription requirements to pricing transparency.

What Is Saxenda Injection UK Treatment and How Does It Work?

Saxenda injection UK prescriptions contain liraglutide 6mg/ml, a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management and subsequently licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. The medication works by mimicking the natural GLP-1 hormone, which regulates appetite and food intake by acting on receptors in the brain that control hunger signals.

Clinical trials demonstrated that patients using Saxenda injection UK treatment alongside lifestyle modifications achieved an average weight loss of 8% of their initial body weight over 56 weeks, compared to 2.6% in the placebo group [2]. The once-daily subcutaneous injection is self-administered using a pre-filled pen, with dosing gradually escalated from 0.6mg to the maintenance dose of 3.0mg over five weeks to minimise gastrointestinal side effects. Our superintendent pharmacist Tarun Kumar emphasises that treatment success depends on combining Saxenda with a reduced-calorie diet and increased physical activity, as the medication enhances but does not replace lifestyle interventions.

The mechanism involves slowing gastric emptying, which prolongs the feeling of fullness after meals, and reducing appetite through central nervous system pathways [3]. Patients typically report decreased hunger, smaller portion sizes, and reduced food cravings within the first few weeks of reaching the therapeutic dose. Treatment should be discontinued if patients have not lost at least 5% of their initial body weight after 12 weeks at the 3.0mg dose, as continued use is unlikely to produce clinically meaningful results.

Liraglutide vs Other GLP-1 Receptor Agonists

While Saxenda injection UK contains liraglutide as a daily injection, newer GLP-1 treatments like semaglutide (Wegovy) offer weekly dosing and dual-action medications like tirzepatide (Mounjaro) combine GLP-1 with GIP receptor agonism for enhanced efficacy. Each option has distinct advantages: liraglutide has the longest safety track record with over 15 years of clinical use, semaglutide provides dosing convenience, and tirzepatide demonstrates superior weight loss outcomes in head-to-head trials [4]. Your prescriber will recommend the most appropriate option based on your medical history, treatment goals, and individual response to therapy.

Saxenda Injection UK Pricing and How to Access Treatment

At Cured Pharmacy, Saxenda injection UK pricing starts from £124.99 per pen, representing the most competitive rate available from UK-registered pharmacies. We maintain transparent upfront pricing with no hidden consultation fees—the price you see is the total cost including clinical assessment by our UK-registered prescribers. Each pre-filled pen contains 18mg of liraglutide (6mg/ml solution), providing approximately 30 days of treatment when used at the maintenance dose of 3.0mg daily.

Accessing Saxenda injection UK treatment requires completion of a free online medical consultation that takes under three minutes. Our clinical team reviews your health history, current medications, and weight management goals to determine suitability. As a prescription-only medication, Saxenda can only be supplied following approval by a UK-registered prescriber in accordance with MHRA regulations and GPhC standards. New patients can Save £20 off their first order using code Weightlossnew, reducing the initial investment while you assess treatment tolerability during the dose escalation phase.

We offer next-day delivery in 100% discreet packaging, with all orders dispatched from our UK-registered pharmacy premises. Patients typically order multiple pens to cover the initial titration period and subsequent maintenance therapy, with our clinical team available via phone (+44 116 4646009) to answer questions about dosing, injection technique, or side effect management throughout your treatment journey.

Clinical Evidence Supporting Saxenda Injection UK Effectiveness

The approval of Saxenda injection UK by the MHRA was based on robust clinical trial data from the SCALE (Satiety and Clinical Adiposity—Liraglutide Evidence) programme, which enrolled over 5,000 participants across multiple international sites [5]. The pivotal SCALE Obesity and Prediabetes trial demonstrated that 63.2% of patients achieved at least 5% weight loss at 56 weeks, compared to 27.1% in the placebo group, while 33.1% achieved the more ambitious target of at least 10% weight loss versus 10.6% with placebo [2].

Long-term data from the SCALE Maintenance trial showed that patients who had already achieved weight loss through lifestyle modifications maintained significantly greater weight reduction when treated with Saxenda injection UK compared to those switched to placebo [6]. Importantly, treatment also produced meaningful improvements in cardiovascular risk factors including reductions in systolic blood pressure, improvements in lipid profiles, and better glycaemic control in patients with prediabetes.

Real-world evidence from UK clinical practice mirrors these trial outcomes, with our experience at Cured Pharmacy confirming that patients who adhere to the full maintenance dose and implement concurrent lifestyle changes achieve the most substantial and sustained results. Treatment response varies individually, and approximately 15-20% of patients discontinue due to gastrointestinal side effects or insufficient weight loss despite proper dosing and lifestyle adherence [7].

Who Should Consider Saxenda Treatment?

Saxenda injection UK is licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea. The medication is not suitable for patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or those with severe renal or hepatic impairment. Pregnant or breastfeeding women should not use Saxenda, and treatment should be discontinued at least two months before planned conception.

How to Use Saxenda Injection UK: Dosing and Administration

Saxenda injection UK is administered once daily at any time of day, with or without food, though maintaining a consistent timing helps establish routine adherence. The medication is injected subcutaneously into the abdomen, thigh, or upper arm using the pre-filled pen device. Patients rotate injection sites to prevent lipodystrophy and ensure consistent absorption. The pen is designed for ease of use with clear dose markings and a simple dial-and-inject mechanism that requires no manual needle attachment.

Dosing follows a mandatory escalation schedule to improve gastrointestinal tolerability: Week 1 starts at 0.6mg daily, increasing to 1.2mg in Week 2, 1.8mg in Week 3, 2.4mg in Week 4, and reaching the maintenance dose of 3.0mg from Week 5 onwards [1]. If patients experience persistent nausea or vomiting at any dose level, they may delay escalation by one week, though prolonged delays should prompt discussion with their prescriber about treatment suitability. The gradual titration significantly reduces the incidence of gastrointestinal side effects compared to starting at the full therapeutic dose.

Each Saxenda injection UK pen must be stored in a refrigerator (2-8°C) before first use and can be kept at room temperature (below 30°C) for up to 30 days after initial use. Patients should inspect the solution before each injection—it should be clear and colourless, with any discolouration or particulate matter indicating the pen should be discarded. Used needles must be disposed of in a sharps container, which we can supply with your order or you can obtain from your local pharmacy or council.

Saxenda Injection UK Side Effects and Safety Considerations

The most common side effects associated with Saxenda injection UK are gastrointestinal in nature, including nausea (affecting approximately 40% of patients), diarrhoea, constipation, vomiting, and dyspepsia [8]. These effects are typically most pronounced during dose escalation and tend to diminish over 2-4 weeks as the body adapts to each new dose level. Taking the injection with food, staying well-hydrated, and eating smaller, more frequent meals can help manage these symptoms.

Hypoglycaemia is uncommon in patients without diabetes using Saxenda injection UK monotherapy, but the risk increases in those taking concurrent antidiabetic medications, particularly sulfonylureas or insulin. Patients with type 2 diabetes should discuss dose adjustments of their existing medications with their prescriber before starting liraglutide. Rare but serious adverse events include pancreatitis (characterised by persistent severe abdominal pain), gallbladder disease, and increased heart rate—any of these symptoms warrant immediate medical attention and treatment discontinuation pending clinical review.

As with all GLP-1 receptor agonists, Saxenda carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though human relevance remains uncertain after extensive post-marketing surveillance [1]. Patients should be counselled about symptoms of medullary thyroid carcinoma (neck lump, persistent hoarseness, dysphagia, dyspnoea) and report these immediately. Our clinical team at Cured Pharmacy provides comprehensive safety information during the consultation process and remains available throughout treatment to address any concerns.

Drug Interactions and Contraindications

Saxenda injection UK slows gastric emptying, which may affect the absorption of oral medications, particularly those requiring rapid onset or narrow therapeutic windows. Patients taking warfarin should monitor INR more frequently when initiating or discontinuing liraglutide. The medication is contraindicated in patients with inflammatory bowel disease or diabetic gastroparesis, as delayed gastric emptying could exacerbate these conditions. Always inform your prescriber of all current medications, including over-the-counter products and herbal supplements, during your consultation.

Saxenda Injection UK vs Alternative Weight Loss Treatments

When comparing Saxenda injection UK to other pharmacological weight loss options, several factors influence treatment selection. Orlistat (Xenical, Alli) works through a different mechanism by blocking fat absorption in the intestine, producing more modest weight loss (approximately 3-5% of body weight) with gastrointestinal side effects related to malabsorbed fat. Orlistat may suit patients who prefer oral medication and have fat-rich diets, though efficacy is generally lower than GLP-1 treatments.

Newer GLP-1 and dual-action medications like semaglutide (Wegovy) and tirzepatide (Mounjaro) offer enhanced weight loss outcomes compared to Saxenda injection UK, with clinical trials showing average reductions of 15-20% of body weight with these agents [4]. However, liraglutide maintains advantages in terms of established long-term safety data, extensive real-world use across diverse populations, and competitive pricing. The daily injection schedule, while more frequent than weekly alternatives, allows for more granular dose adjustments and quicker washout if side effects necessitate discontinuation.

Non-pharmacological approaches including behavioural therapy, very-low-calorie diets, and bariatric surgery remain important components of comprehensive weight management. NICE guidelines recommend considering pharmacotherapy when lifestyle interventions alone have not achieved adequate weight loss, with medication serving as an adjunct rather than replacement for dietary modification and physical activity [3]. Your prescriber will help determine whether Saxenda injection UK represents the most appropriate option based on your individual circumstances, previous treatment responses, and clinical goals.

Combining Saxenda with Lifestyle Modifications

Optimal outcomes with Saxenda injection UK require concurrent implementation of a reduced-calorie diet (typically 500-1000 kcal daily deficit) and at least 150 minutes of moderate-intensity physical activity per week, aligned with NHS weight management recommendations. Our clinical team can provide guidance on sustainable dietary changes and appropriate exercise progression, though patients may also benefit from referral to registered dietitians or structured weight management programmes. The medication enhances adherence to lifestyle modifications by reducing hunger and cravings, creating a synergistic effect that produces superior results compared to either intervention alone.

Scientific References

1. Electronic Medicines Compendium. (2023). Saxenda 6 mg/ml solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines.org.uk. [accessed 13 August 2026]
2. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE Guidelines. [accessed 13 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 13 August 2026]
5. Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V., Hale, P. M., & Aronne, L. (2013). Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International Journal of Obesity, 37(11), 1443-1451. [accessed 13 August 2026]
6. Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V., Hale, P. M., & Aronne, L. (2013). Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss. International Journal of Obesity, 37(11), 1443-1451. [accessed 13 August 2026]
7. Lean, M. E., Carraro, R., Finer, N., Hartvig, H., Lindegaard, M. L., Rössner, S., ... & Astrup, A. (2014). Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. International Journal of Obesity, 38(5), 689-697. [accessed 13 August 2026]
8. Medicines and Healthcare products Regulatory Agency. (2023). Liraglutide (Saxenda): updated advice on reporting of side effects. Drug Safety Update, 16(8). [accessed 13 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.